Download PDF
Clin Colon Rectal Surg 2016; 29(02): 080-084
DOI: 10.1055/s-0036-1580633
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Perioperative Considerations in Crohn Disease and Ulcerative Colitis

T. Paul Nickerson
1   Department of Surgery, Mayo Clinic, Rochester, Minnesota
,
Amit Merchea
2   Division of Colon and Rectal Surgery, Mayo Clinic, Jacksonville, Florida
› Author Affiliations
Further Information

Publication History

Publication Date:
26 May 2016 (online)

Also available at
    Permissions and Reprints

Abstract

The management of inflammatory bowel disease (IBD) is medically and surgically complex. Numerous patient- and disease-oriented factors must be considered in treating patients with IBD, including nutritional replenishment/support, effect of immunosuppressive medications, extent of resection, and use of proximal diversion. Perioperative planning and optimization of the patient is imperative to ensuring favorable outcomes and limiting morbidity. These perioperative considerations in Crohn disease and ulcerative colitis are reviewed here.

Keywords

Crohn disease - ulcerative colitis - perioperative management - steroids - immunomodulators - biologics - nutrition
 

  • References

  • 1 Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141 (1) 90-97
    CrossrefPubMedGoogle Scholar
  • 2 Tay GS, Binion DG, Eastwood D, Otterson MF. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery 2003; 134 (4) 565-572 , discussion 572–573
    CrossrefPubMedGoogle Scholar
  • 3 Razack R, Seidner DL. Nutrition in inflammatory bowel disease. Curr Opin Gastroenterol 2007; 23 (4) 400-405
    CrossrefPubMedGoogle Scholar
  • 4 Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum 2000; 43 (8) 1141-1145
    CrossrefPubMedGoogle Scholar
  • 5 Alves A, Panis Y, Bouhnik Y, Pocard M, Vicaut E, Valleur P. Risk factors for intra-abdominal septic complications after a first ileocecal resection for Crohn's disease: a multivariate analysis in 161 consecutive patients. Dis Colon Rectum 2007; 50 (3) 331-336
    CrossrefPubMedGoogle Scholar
  • 6 Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis 2008; 14 (8) 1105-1111
    CrossrefPubMedGoogle Scholar
  • 7 Wagner IJ, Rombeau JL. Nutritional support of surgical patients with inflammatory bowel disease. Surg Clin North Am 2011; 91 (4) 787-803 , viii
    CrossrefPubMedGoogle Scholar
  • 8 Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn's disease. Aliment Pharmacol Ther 2014; 40 (9) 1009-1022
    CrossrefPubMedGoogle Scholar
  • 9 Larson DW, Lovely JK, Cima RR , et al. Outcomes after implementation of a multimodal standard care pathway for laparoscopic colorectal surgery. Br J Surg 2014; 101 (8) 1023-1030
    CrossrefPubMedGoogle Scholar
  • 10 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc 2011; 86 (8) 748-757
    CrossrefPubMedGoogle Scholar
  • 11 Furst MB, Stromberg BV, Blatchford GJ, Christensen MA, Thorson AG. Colonic anastomoses: bursting strength after corticosteroid treatment. Dis Colon Rectum 1994; 37 (1) 12-15
    CrossrefPubMedGoogle Scholar
  • 12 Tzivanakis A, Singh JC, Guy RJ, Travis SP, Mortensen NJ, George BD. Influence of risk factors on the safety of ileocolic anastomosis in Crohn's disease surgery. Dis Colon Rectum 2012; 55 (5) 558-562
    CrossrefPubMedGoogle Scholar
  • 13 Subramanian V, Saxena S, Kang JY, Pollok RC. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 2008; 103 (9) 2373-2381
    CrossrefPubMedGoogle Scholar
  • 14 Mascarenhas C, Nunoo R, Asgeirsson T , et al. Outcomes of ileocolic resection and right hemicolectomies for Crohn's patients in comparison with non-Crohn's patients and the impact of perioperative immunosuppressive therapy with biologics and steroids on inpatient complications. Am J Surg 2012; 203 (3) 375-378 , discussion 378
    CrossrefPubMedGoogle Scholar
  • 15 Sharma A, Chinn BT. Preoperative optimization of Crohn disease. Clin Colon Rectal Surg 2013; 26 (2) 75-79
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Eriksen TF, Lassen CB, Gögenur I. Treatment with corticosteroids and the risk of anastomotic leakage following lower gastrointestinal surgery: a literature survey. Colorectal Dis 2014; 16 (5) O154-O160
    CrossrefPubMedGoogle Scholar
  • 17 Beddy D, Dozois EJ, Pemberton JH. Perioperative complications in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17 (7) 1610-1619
    CrossrefPubMedGoogle Scholar
  • 18 Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125 (2) 320-327
    CrossrefPubMedGoogle Scholar
  • 19 Mahadevan U, Loftus Jr EV, Tremaine WJ , et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002; 8 (5) 311-316
    CrossrefPubMedGoogle Scholar
  • 20 Lichtenstein GR, Feagan BG, Cohen RD , et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107 (9) 1409-1422
    CrossrefPubMedGoogle Scholar
  • 21 Lichtenstein GR, Feagan BG, Cohen RD , et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4 (5) 621-630
    CrossrefPubMedGoogle Scholar
  • 22 Colombel JF, Loftus Jr EV, Tremaine WJ , et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99 (5) 878-883
    CrossrefPubMedGoogle Scholar
  • 23 Indar AA, Young-Fadok TM, Heppell J, Efron JE. Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients. World J Surg 2009; 33 (5) 1049-1052
    CrossrefPubMedGoogle Scholar
  • 24 Fraser CG, Preuss FS, Bigford WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J Am Med Assoc 1952; 149 (17) 1542-1543
    CrossrefPubMedGoogle Scholar
  • 25 Beck DE, Opelka FG. Perioperative steroid use in colorectal patients. Results of a survey. Dis Colon Rectum 1996; 39 (9) 995-999
    CrossrefPubMedGoogle Scholar
  • 26 Zaghiyan K, Melmed GY, Berel D, Ovsepyan G, Murrell Z, Fleshner P. A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery. Ann Surg 2014; 259 (1) 32-37
    CrossrefPubMedGoogle Scholar
  • 27 Hicks CW, Wick EC, Salvatori R, Ha CY. Perioperative corticosteroid management for patients with inflammatory bowel disease. Inflamm Bowel Dis 2015; 21 (1) 221-228
    CrossrefPubMedGoogle Scholar
  • 28 Canedo J, Lee SH, Pinto R, Murad-Regadas S, Rosen L, Wexner SD. Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?. Colorectal Dis 2011; 13 (11) 1294-1298
    CrossrefPubMedGoogle Scholar
  • 29 Pinna-Pintor M, Arese P, Bona R , et al. Severe steroid-unresponsive ulcerative colitis: outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 2000; 43 (5) 609-613 , discussion 613–614
    CrossrefPubMedGoogle Scholar
  • 30 Hyde GM, Jewell DP, Kettlewell MG, Mortensen NJ. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44 (10) 1436-1440
    CrossrefPubMedGoogle Scholar
  • 31 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg 2011; 15 (2) 267-276
    CrossrefPubMedGoogle Scholar
  • 32 Hanauer SB, Feagan BG, Lichtenstein GR , et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317) 1541-1549
    CrossrefPubMedGoogle Scholar
  • 33 Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12 (10) 1730-1736 , discussion 1736–1737
    CrossrefPubMedGoogle Scholar
  • 34 Marchal L, D'Haens G, Van Assche G , et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19 (7) 749-754
    CrossrefPubMedGoogle Scholar
  • 35 Nasir BS, Dozois EJ, Cima RR , et al. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg 2010; 14 (12) 1859-1865 , discussion 1865–1866
    CrossrefPubMedGoogle Scholar
  • 36 Waterman M, Xu W, Dinani A , et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013; 62 (3) 387-394
    CrossrefPubMedGoogle Scholar
  • 37 Myrelid P, Marti-Gallostra M, Ashraf S , et al. Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy. Br J Surg 2014; 101 (5) 539-545
    CrossrefPubMedGoogle Scholar
  • 38 Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease—a nationwide cohort study. Aliment Pharmacol Ther 2013; 37 (2) 214-224
    CrossrefPubMedGoogle Scholar
  • 39 Appau KA, Fazio VW, Shen B , et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg 2008; 12 (10) 1738-1744
    CrossrefPubMedGoogle Scholar
  • 40 Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients. Am J Gastroenterol 2013; 108 (4) 583-593
    CrossrefPubMedGoogle Scholar
  • 41 Strong SA. Inflammatory bowel disease surgery in the biologic therapy era. Curr Opin Gastroenterol 2012; 28 (4) 349-353
    PubMedGoogle Scholar
  • 42 Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18 (16) 1861-1870
    CrossrefPubMedGoogle Scholar
  • 43 Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 2008; 51 (8) 1202-1207 , discussion 1207–1210
    CrossrefPubMedGoogle Scholar
  • 44 Selvasekar CR, Cima RR, Larson DW , et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007; 204 (5) 956-962 , discussion 962–963
    CrossrefPubMedGoogle Scholar
  • 45 Ferrante M, D'Hoore A, Vermeire S , et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15 (7) 1062-1070
    CrossrefPubMedGoogle Scholar
  • 46 Hicks CW, Hodin RA, Bordeianou L. Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA Surg 2013; 148 (7) 658-664
    CrossrefPubMedGoogle Scholar
  • 47 Pandey S, Luther G, Umanskiy K , et al. Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging?. Dis Colon Rectum 2011; 54 (3) 306-310
    CrossrefPubMedGoogle Scholar
  • 48 Bikhchandani J, Polites SF, Wagie AE, Habermann EB, Cima RR. National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. Dis Colon Rectum 2015; 58 (2) 199-204
    CrossrefPubMedGoogle Scholar
  • 49 Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9 (2) 98-103
    CrossrefPubMedGoogle Scholar
  • 50 Hong MK, Craig Lynch A, Bell S , et al. Faecal diversion in the management of perianal Crohn's disease. Colorectal Dis 2011; 13 (2) 171-176
    CrossrefPubMedGoogle Scholar
  • 51 Mathis KLPJ, Tiret E, Bemelman E , et al. Clinical effectiveness and outcome of diversion in refractory Crohn's colitis with and without perianal fistula. Dis Colon Rectum 2015; 58 (5) e166
    PubMedGoogle Scholar
  • 52 Schaden D, Schauer G, Haas F, Berger A. Myocutaneous flaps and proctocolectomy in severe perianal Crohn's disease—a single stage procedure. Int J Colorectal Dis 2007; 22 (12) 1453-1457
    CrossrefPubMedGoogle Scholar